Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
AnemiaLiver DiseaseHypoxemia
Interventions
DRUG

Pegylated Interferon Alpha2b

Weekly subcutaneous injection of 1 microgram/kg/week

OTHER

Standard care

Standard care

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Augusta University

OTHER

collaborator

Unity Health Toronto

OTHER

collaborator

Schering-Plough

INDUSTRY

lead

Mayo Clinic

OTHER